Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs
Synopsis
The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.
Shares of Mangoceuticals, Inc. (MGRX) jumped 23% in the pre-market session on Thursday after the telehealth company announced the launch of programs that provide direct access to authentic weight loss medicines from drugmakers Eli Lilly and Novo Nordisk.
The company said that it has launched two programs called MangoRx Direct and PeachesRx Direct to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.
The obesity medications will be made available to both MangoRx and PeachesRx customers through Eli Lilly’s LillyDirect Self-Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.